Abciximab
drugOn this page
Also known as Abciximab (genetical recombination)C7E3Reopro
Summary
Abciximab (CHEMBL1201584) is an approved antibody (ATC B01AC13); indicated across 10 conditions including thrombotic disease and intermediate coronary syndrome.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: B01AC13
- Indications: 10 conditions
- Clinical trials: 38
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201584 |
| Name | Abciximab |
| Type | Antibody |
| Max phase | 4 |
| ATC | B01AC13 |
Also known as: Abciximab, Abciximab (genetical recombination), C7E3, Reopro, ABCIXIMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| integrin αIIbβ3 | Binding |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
10 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| thrombotic disease | 4 | MONDO:0000831 | HP:0004419 |
| intermediate coronary syndrome | 4 | MONDO:0006805 | EFO:1000985 |
| myocardial infarction | 3 | MONDO:0005068 | EFO:0000612 |
| stroke disorder | 3 | MONDO:0005098 | EFO:0000712 |
| ST-elevation myocardial infarction | 3 | MONDO:0041656 | EFO:0008585 |
| brain ischemia | 3 | MONDO:0005299 | MONDO:0005299 |
| acute disease | 3 | MONDO:0020683 | MONDO:0020683 |
| acute myocardial infarction | 3 | MONDO:0004781 | EFO:0008583 |
| internal carotid artery stenosis | 1 | MONDO:0005189 | EFO:0002615 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 38.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 15 |
| PHASE3 | 11 |
| PHASE2 | 5 |
| Not specified | 4 |
| PHASE2/PHASE3 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00133003 | PHASE4 | COMPLETED | Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2) |
| NCT00133250 | PHASE4 | COMPLETED | Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3) |
| NCT00169819 | PHASE4 | COMPLETED | EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study |
| NCT00229515 | PHASE4 | UNKNOWN | Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI |
| NCT00320229 | PHASE4 | TERMINATED | Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen |
| NCT00354406 | PHASE4 | COMPLETED | Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty |
| NCT00373451 | PHASE4 | COMPLETED | Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome |
| NCT00383136 | PHASE4 | COMPLETED | FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab |
| NCT00420030 | PHASE4 | COMPLETED | Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock |
| NCT00440778 | PHASE4 | COMPLETED | A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI |
| NCT00440895 | PHASE4 | COMPLETED | A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI |
| NCT00986050 | PHASE4 | COMPLETED | Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial Infarction |
| NCT01158846 | PHASE4 | UNKNOWN | Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI |
| NCT01475552 | PHASE4 | COMPLETED | Tailored Antiplatelet Therapy During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus |
| NCT01499407 | PHASE4 | UNKNOWN | Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction |
| NCT00046228 | PHASE3 | COMPLETED | A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse) |
| NCT00073372 | PHASE3 | TERMINATED | A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II) |
| NCT00126139 | PHASE3 | TERMINATED | Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis |
| NCT00156611 | PHASE2/PHASE3 | UNKNOWN | Rio Trial - ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease |
| NCT00167765 | PHASE3 | TERMINATED | Abciximab in Wake-up Stroke |
| NCT00269880 | PHASE3 | COMPLETED | A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention. |
| NCT00269893 | PHASE3 | COMPLETED | A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty |
| NCT00269906 | PHASE3 | COMPLETED | A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty |
| NCT00299377 | PHASE2/PHASE3 | COMPLETED | Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI |
| NCT00426751 | PHASE3 | COMPLETED | Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI) |
| NCT00638638 | PHASE3 | UNKNOWN | Myocardial Infarction With ST-Elevation |
| NCT00712101 | PHASE3 | COMPLETED | Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction |
| NCT02181985 | PHASE3 | COMPLETED | Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI) |
| NCT00046293 | PHASE2 | COMPLETED | ReoPro and Retavase to Treat Acute Stroke |
| NCT00163254 | PHASE2 | UNKNOWN | Below Study - Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee |
| NCT00178451 | PHASE1/PHASE2 | WITHDRAWN | Stroke Prevention With Abciximab in Carotid Endarterectomy |
| NCT00260416 | PHASE2 | COMPLETED | Primary Angioplasty for Acute Myocardial Infarction in Patients With Symptom Duration Above 12 Hours |
| NCT01932554 | PHASE2 | WITHDRAWN | Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis |
| NCT03087539 | PHASE2 | UNKNOWN | Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI Patients |
| NCT00379418 | Not specified | COMPLETED | Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients |
| NCT00685464 | Not specified | COMPLETED | Intravenous Versus Intracoronary Use of Abciximab |
| NCT00927615 | Not specified | UNKNOWN | Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO) |
| NCT02105870 | Not specified | UNKNOWN | A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).